SG151336A1 - 1,3,4-oxadiazol-2-ones as ppar delta - Google Patents

1,3,4-oxadiazol-2-ones as ppar delta

Info

Publication number
SG151336A1
SG151336A1 SG200902266-6A SG2009022666A SG151336A1 SG 151336 A1 SG151336 A1 SG 151336A1 SG 2009022666 A SG2009022666 A SG 2009022666A SG 151336 A1 SG151336 A1 SG 151336A1
Authority
SG
Singapore
Prior art keywords
oxadiazol
ones
ppar delta
oxadiazalones
ppardelta
Prior art date
Application number
SG200902266-6A
Other languages
English (en)
Inventor
Daniel G Mcgarry
Jochen Goerlitzer
Stefanie Keil
Karen Chandross
Jean Merrill
Wolfgang Wendler
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of SG151336A1 publication Critical patent/SG151336A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG200902266-6A 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones as ppar delta SG151336A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55842004P 2004-04-01 2004-04-01

Publications (1)

Publication Number Publication Date
SG151336A1 true SG151336A1 (en) 2009-04-30

Family

ID=34972960

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200902266-6A SG151336A1 (en) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones as ppar delta

Country Status (15)

Country Link
US (2) US7638539B2 (ru)
EP (1) EP1781648A2 (ru)
JP (1) JP4813461B2 (ru)
CN (1) CN1956984B (ru)
AU (1) AU2005230838A1 (ru)
BR (1) BRPI0508180A (ru)
CA (1) CA2561230A1 (ru)
IL (1) IL178166A0 (ru)
MA (1) MA28563B1 (ru)
NO (1) NO20064951L (ru)
NZ (1) NZ549823A (ru)
RU (1) RU2365589C2 (ru)
SG (1) SG151336A1 (ru)
WO (1) WO2005097763A2 (ru)
ZA (1) ZA200607852B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4813460B2 (ja) * 2004-04-01 2011-11-09 アベンティス・ファーマスーティカルズ・インコーポレイテツド ＰＰＡＲδモジュレーターとしての１，３，４−オキサジアゾール−２−オン及びその使用
CN1956984B (zh) * 2004-04-01 2010-06-09 安万特药物公司 1,3,4-二唑-2-酮作为PPAR-δ调节剂
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
EP1979311B1 (en) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
WO2011041584A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
BRPI1107312B1 (pt) * 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
CA2923422C (en) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Use of a ppar-delta agonist for treating muscle atrophy
KR101715127B1 (ko) * 2015-10-30 2017-03-15 한국과학기술연구원 시신경 척수염 예방 또는 치료용 피리미딘 카복실레이트 유도체
CN114195786B (zh) * 2020-09-18 2023-08-22 凯思凯迪（上海）医药科技有限公司 新型fxr小分子激动剂制备及其用途
CN114195777B (zh) * 2020-09-18 2023-06-20 凯思凯迪（上海）医药科技有限公司 新型fxr小分子激动剂制备及其用途
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895953A (en) * 1987-09-30 1990-01-23 American Home Products Corporation 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
WO2000078313A1 (en) * 1999-06-18 2000-12-28 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
WO2001017994A1 (en) * 1999-09-08 2001-03-15 Glaxo Group Limited Oxazole ppar antagonists
JP4145230B2 (ja) * 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
JP4813460B2 (ja) * 2004-04-01 2011-11-09 アベンティス・ファーマスーティカルズ・インコーポレイテツド ＰＰＡＲδモジュレーターとしての１，３，４−オキサジアゾール−２−オン及びその使用
CN1956984B (zh) * 2004-04-01 2010-06-09 安万特药物公司 1,3,4-二唑-2-酮作为PPAR-δ调节剂

Also Published As

Publication number Publication date
US7872032B2 (en) 2011-01-18
NO20064951L (no) 2006-10-30
US7638539B2 (en) 2009-12-29
WO2005097763A2 (en) 2005-10-20
CN1956984B (zh) 2010-06-09
MA28563B1 (fr) 2007-04-03
EP1781648A2 (en) 2007-05-09
AU2005230838A1 (en) 2005-10-20
IL178166A0 (en) 2006-12-31
CN1956984A (zh) 2007-05-02
RU2006138494A (ru) 2008-05-10
ZA200607852B (en) 2008-07-30
WO2005097763A3 (en) 2005-12-15
BRPI0508180A (pt) 2007-08-07
JP2007531764A (ja) 2007-11-08
JP4813461B2 (ja) 2011-11-09
NZ549823A (en) 2009-12-24
US20090275621A1 (en) 2009-11-05
US20070099964A1 (en) 2007-05-03
RU2365589C2 (ru) 2009-08-27
CA2561230A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
IL178167A0 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
GB0318447D0 (en) Therapeutic agents
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
NZ539841A (en) Hydroxyethylamine derivatives for the treatment of alzheimer's disease
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
GB0225475D0 (en) Therapeutic agents
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
MXPA05014201A (es) Pirazolo [3,4-b] piridin-6-onas como inhibidores de la gsk-3.
PL1697394T3 (pl) Inhibitory COMT
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
WO2003070728A3 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
EP2073635A4 (en) MACROCYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER